Notice NOT-AG-23-029 from the NIH Guide for Grants and Contracts

Notice NOT-AI-23-048 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-23-213 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to provide opportunities for eligible small business concerns (SBCs) to develop interactive digital media (IDM) biomedical science resources for pre-college students and teachers.

Funding Opportunity RFA-DK-23-014 from the NIH Guide for Grants and Contracts. The NIDDK Catalyst Award is designed to complement NIDDK's traditional, investigator-initiated grant programs by supporting individual scientists who propose pioneering and transformational studies in topic areas of interest to NIDDK's Division of Diabetes, Endocrinology and Metabolic Diseases, and to NIDDK's Division of Digestive Diseases and Nutrition. Applications should be focused on major scientific challenges, and have the potential to produce an unusually high impact on diseases and conditions that are central to the mission of these two divisions within NIDDK. To be considered responsive to this initiative, the proposed research should reflect new and novel scientific directions that are distinct from concepts and approaches being pursued in the investigators research program or elsewhere.

Funding Opportunity PAR-23-194 from the NIH Guide for Grants and Contracts. The goal of this FOA is to support doctoral candidates from a variety of academic disciplines for up to two years for the completion of the doctoral dissertation research project. Research projects should align with NIDA funding priorities detailed here (https://www.drugabuse.gov/funding/funding-priorities) or within the NIDA Strategic Plan (https://www.drugabuse.gov/about-nida/2016-2020-nida-strategic-plan). This award will facilitate the entry of promising new investigators into the field of substance use/substance use disorder (SU(D) research, enhancing the pool of highly talented SU(D) researchers. Applications are particularly encouraged from those who can contribute to diversifying the research workforce as described in the Notice of NIH's Interest in Diversity (NOT-OD-20-031).

Notice NOT-RM-23-018 from the NIH Guide for Grants and Contracts

Notice NOT-AI-23-045 from the NIH Guide for Grants and Contracts

Notice NOT-MH-23-255 from the NIH Guide for Grants and Contracts

Notice NOT-MH-23-260 from the NIH Guide for Grants and Contracts

Notice NOT-MH-23-280 from the NIH Guide for Grants and Contracts

From £41,935, with benefits, subject to skills and experience.: The Francis Crick Institute: This postdoc fellow will join Pontus Skoglund and the Crick Ancient Genomics laboratory in applying and developing proteomic approaches. London (Central), London (Greater)

Competitive: CK Group: CK Group are recruiting for a highly motivated Computational Chemist to join a leading biopharmaceutical company focused on therapeutic areas in inflammation diseases, neurology and... Cambridge

Funding Opportunity PAR-23-207 from the NIH Guide for Grants and Contracts. The goal of this Funding Opportunity Announcement (FOA) is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD). The findings are expected to advance mechanistic understanding of both biobehavioral and neurobiological pathways leading to NPS. Findings may also provide insight into novel therapeutic targets that can be advanced into interventions to treat and prevent the development of NPS in AD and/or ADRD

Funding Opportunity PAR-23-208 from the NIH Guide for Grants and Contracts. The goal of this Funding Opportunity Announcement (FOA) is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD). The findings are expected to advanceadavnce mechanistic understanding of both biobehavioral and neurobiologfical pathways leading to NPS. Findings may also provide insight into novel therapeutic targets that can be advanced into interventions to treat and prevent the development of NPS in AD and/or ADRD.

Funding Opportunity PAR-23-218 from the NIH Guide for Grants and Contracts. Goal is to have experimental models that can accurately reproduce neuropathological signatures and clinically relevant neurodegenerative, biochemical and behavioral sequelae as those seen in human subjects post-TBI AD/ADRDs. Requirement: Interdisciplinary Team science approach / consortium type of applications. Applications will include multiple sites (3-5 sites) developing and/or testing specific models that will then implement a test of reproducibility across the consortium. Requirement: Must have a clinician with expertise in post-TBI ADRD on the team. Encourage having neuropathologists as consultants on grants. Requirement: Models developed through this FOA will be required to share their model, model details and related standards with the VA-funded interagency preclinical resource center - PRECISE TBI Studies investigating neurodegeneration of white matter and chronic inflammation in post-TBI AD/ADRDs are highly encouraged. Innovative applications reaching beyond the current AD/ADRD models are highly encouraged.

Notice NOT-DA-23-027 from the NIH Guide for Grants and Contracts

£35,000 to £40,000: Vaccitech: Reference based and de novo viral genome assembly, including assessing and filtering reads, and reporting quality of genome assembly Harwell, Didcot

Notice NOT-AI-23-052 from the NIH Guide for Grants and Contracts

Notice NOT-EB-23-004 from the NIH Guide for Grants and Contracts

Notice NOT-DA-24-010 from the NIH Guide for Grants and Contracts